Cellular Intelligence

Today we’re sharing a defining moment for Cellular Intelligence. We have entered into an agreement with @novonordisk to acquire STEM-PD, a Phase 2-ready allogeneic cell therapy program for Parkinson’s disease. Alongside the acquisition, Novo Nordisk is making a strategic investment in Cellular Intelligence. This is one of the most advanced cell therapy programs in Parkinson’s. The program has an FDA-cleared IND for Phase 2 and Fast Track Designation, following completion of Phase 1/2 dosing in the underlying academic clinical program, STEM-PD. This is more than an asset acquisition. It marks the beginning of an AI-native era for cell replacement therapy. One where biology is no longer destiny, but design. Read all about it here: cellularintelligence.com/stem-pd?utm-so… #CellTherapy #ParkinsonsDisease #Biotech #AIinBiotech #TechBio STEM-PD is an investigational therapy; its safety and efficacy have not been established.

Today is a milestone for Parkinson's research, and it belongs to Lund. A team led from Lund University has published the first-in-human clinical trial results for a stem-cell-derived cell therapy in Parkinson's disease, in Nature Medicine. This is a landmark for regenerative medicine, built on four decades of dopamine-cell science pioneered at Lund, and a goal the field has worked toward for a generation. Our congratulations to the entire STEM-PD team: 🔹 Malin Parmar, Project Lead, Lund University 🔹 Gesine Paul-Visse, Principal Investigator, Lund University and Skåne University Hospital 🔹 Roger Barker, Clinical Lead and Principal Investigator, University of Cambridge and Cambridge University Hospitals 🔹 Håkan Widner, Sponsor Representative and Co-Investigator, Lund University and Skåne University Hospital 🔹 Hjálmar Bjartmarz, Co-Investigator and Neurosurgeon, Skåne University Hospital 🔹 Agnete Kirkeby, Pre-clinical Development Lead, Lund University and University of Copenhagen 🔹 Paola Piccini, Brain Imaging, Imperial College London 🔹 Oskar Hansson, PET Imaging, Lund University 🔹 Ruben Smith, PET Imaging, Lund University and Skåne University Hospital The trial was managed by the Cambridge Clinical Trials Unit Neuroscience theme and the Skåne University Hospital neurology research unit, with partners at University College London, and conducted in collaboration with Novo Nordisk. Cellular Intelligence is proud to lead the next phase of STEM-PD's clinical development, including a planned Phase II trial. Today the moment belongs to Lund and the team who brought it here. Congratulations to all of them. 🔗 Read the study in Nature Medicine: nature.com/articles/s4159…

How is AI-bio moving from concept to clinical-stage impact? Cellular Intelligence CEO @MichaBreakstone sat down with @CNBC 's @jonfortt to discuss how we're turning biology into a predictive engineering discipline. Cell signaling is a language. Just as foundation models learned to predict ours, we're learning to predict theirs. When we get that right, we step into the era of programmable biology. 🎬 Watch the full conversation here: cnbc.com/video/2026/06/…

Founders & Leadership Team: @MichaBreakstone, Olivier Pourquie, @JShendure, @arjunrajlab, @KleinLabHMS, Cliff Tabin, @TweetKJBrown, Tzvika Cohen, @SamanthaDStrass, Nuno Mendonça, Marianne Stemann Andersen.

Keynote & Speakers: Mads Krogsgaard Thomsen, @nasdaily, @MatttBuckley, Thomas Carlsen, @StephanChr25527, @andreascleve, @johncumbers, @VitalayFomin, Gunner Laine Hardy, @kim_bak_jensen, Petrina Kamya, @Kirkeby_Lab, @MatLegut, @aijamayrock, @jb_michel, Jens Nielsen, @ParmarLab , Travis Potter, Tali Raveh, @ArmonSharei, @ReshefShilon, @NTallapragada, @aloktayi, @VallierLab, @PeterAksel

What is the future of AI x Bio? Yesterday in Copenhagen, we set out to answer exactly that. At the @novonordiskfond headquarters, we convened leaders across AI, biology, regenerative medicine, venture, and company building for a day-long symposium on Engineering Cell Fate—and what we believe will become the next AlphaFold moment for biology. 🧵

This week at the @KeystoneSymp on Computational Advances in Drug Discovery, our VP of Strategy @SamanthaDStrass gave a spotlight talk, and @baagmery, Principal Scientist in Computational Biology, presented on the poster floor — joining the conversation at the frontier of computational drug discovery. Their talk and poster showcased our multiplexed platform and its ability to generate data at unprecedented scale — the foundation for our work toward a Universal Virtual Cell-Signaling Model that predicts context-dependent signaling response and, ultimately, controls cell fate. This unlocks a range of applications: iPSC-based disease modeling, drug response prediction, target identification, and protocol design for cell therapies. These capabilities turn biology from a trial-and-error science into predictive engineering. Thank you to Keystone Symposia for the opportunity to share our work. We're building a future where biology is no longer destiny, but design. #ksdrugdiscovery2026 @arjunrajlab, Kristy Brown, @KleinLabHMS, Olivier Pourquié

We are incredibly energized by the breakthroughs happening alongside us, and believe that as we learn causal cellular grammar, we are building a future where biology is no longer destiny, but design.

By capturing this scale, we can look at biology not as static states, but as dynamic transitions. We are moving away from empirical trial-and-error to essentially learning the grammar of cellular decision-making, which fundamentally transforms how we can engineer cell therapies and model disease.

Today, our CEO @MichaBreakstone joined a brilliant panel alongside @iamjohnnyyu from @tahoe_ai and @glebkuz from @ManifoldBio—masterfully moderated by @FabioZB_I of Polyphron—to answer a pivotal question: Why now?  🧵

Our CEO @MichaBreakstone just stepped off the stage at #SynBioBeta2026. The energy in the room was electric, confirming what we've believed since day one at Cellular Intelligence: Biology is ready to be transformed from trial-and-error into a true engineering discipline. Thank you @SynBioBeta for the platform to share our vision. We are building a future where biology is no longer destiny, but design.